In vitro and in vivo effect of IFNα on B16F10 melanoma in two models: Subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice)

Biomedicine and Pharmacotherapy

Volumn 63, Issue 4, 2009, Pages 305-312

  Conesa, Cristina Martínez ^a   Sánchez, Nuria Álvarez ^b   Ortega, Vicente Vicente ^b   Reverte, Juana García ^b   Carpe, Fernando Pascual ^b   Aranda, Matilde Campos ^b  

^a INSTITUTO MURCIANO DE INVESTIGACIÓN Y DESARROLLO AGRARIO Y ALIMENTARIO IMIDA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

B16F10; Interferon alpha; Melanoma

Indexed keywords

ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CANCER INVASION; CANCER TRANSPLANTATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA B16; MELANOMA CELL; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; SUBCUTANEOUS METASTASIS; SUBCUTANEOUS TISSUE; SWISS WEBSTER MOUSE; TUMOR WEIGHT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERFERON ALFA-2A; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 64749083992     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.07.092     Document Type: Article

References (33)

1. Autier P. Perspectives in melanoma prevention: the case of sunbeds. Eur J Cancer 40 (2004) 2367-2376
2. Horn-Ross P.L. Melanoma in the Greater San Francisco Bay Area 1988-2000. Available from URL: (March 2003). http://www.nccc.org/pdf/poc/melanoma_factsheet_88-2000.pdf Northern California Cancer Center (serial online) cited
3. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 3 (2005) 481-488
4. Sáenz S., Conejo-Mir J., and Cayuela A. Melanoma epidemiology in Spain. Actas Dermosifiliogr 96 7 (2005) 411-418
5. de Vries E., and Coebergh J.W. Cutaneous malignant melanoma in Europe. Eur J Cancer 40 16 (2004) 2355-2366
6. Leiter U., Meier F., Schittek B., and Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 86 4 (2004) 172-178
7. Yano H., Yanai Y., Momosaki S., Ogasawara S., Akiba J., Kojiro S., et al. Growth inhibitory effects of interferon-alpha subtypes vary according to human liver cancer cell lines. J Gastroenterol Hepatol 21 11 (2006) 1720-1725
8. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S.A., et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202 2 (2005) 323-335
9. Avnet S., Cenni E., Perut F., Granchi D., Brandi M.L., Giunti A., et al. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. Int J Oncol 30 2 (2007) 469-476
10. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 2 (2002) 119-134
11. Håkansson A., Gustafsson B., Krysander L., and Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74 5 (1996) 670-676
12. Håkansson A., Gustafsson B., Krysander L., Bergenwald C., Sander B., and Håkansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 18 1 (1998) 33-39
13. Mohr P., Wechenthal M., and Hauschild A. Adjuvant therapy in melanoma. Onkologie 26 3 (2003) 227-233
14. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47 4 (1987) 943-946
15. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47 4 (1987) 936-942
16. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 3 (1988) 589-601
17. Rodríguez Vicente J., Vicente Ortega V., and Canteras Jordana M. Valor del ensayo calorimétrico en el estudio del crecimiento y citotoxicidad in vitro de líneas de melanoma. Patología 30 1 (1997) 18-27
18. Lentini A., Autuori F., Mattioli P., Caraglia M., Abbruzzese A., and Beninati S. Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis. Eur J Cancer 36 12 (2000) 1572-1577
19. Maellaro E., Pacenti L., Del Bello B., Valentini M.A., Mangiavacchi P., De Felice C., et al. Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br J Dermatol 148 6 (2003) 1115-1124
20. Grebenová D., Kuzelová K., Fuchs O., Halada P., Havlícek V., Marinov I., et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 32 1 (2004) 262-269
21. Craven R.A., Stanley A.J., Hanrahan S., Totty N., Jackson D.P., Popescu R., et al. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. Proteomics 4 12 (2004) 3998-4009
22. Krepler C., Certa U., Wacheck V., Jansen B., Wolff K., and Pehamberger H. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 123 4 (2004) 664-669
23. Lesinski G.B., Kondadasula S.V., Crespin T., Shen L., Kendra K., Walker M., et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 96 17 (2004) 1331-1342
24. + lymphocytes during chemoimmunotherapy in metastatic melanoma. Melanoma Res 14 6 (2004) 493-500
25. Yang H., Dithmar S., and Grossniklaus H.E. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci 45 7 (2004) 2056-2064
26. Gutman H., Schachter J., Stopel E., Gutman R., and Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer 94 3 (2002) 780-785
27. Wang L., Wu W.Z., Sun H.C., Wu X.F., Qin L.X., Liu Y.K., et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7 5 (2003) 587-594
28. Hejna M., Raderer M., and Zielinski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91 1 (1999) 22-36
29. Engelberg H. Actions of heparin that may affect the malignant process. Cancer 85 2 (1999) 257-272
30. Nieswandt B., Hafner M., Echtenacher B., and Männel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer 59 6 (1999) 1295-1300
31. Palumbo J.S., Talmage K.E., Massari J.V., La Jeunesse C.M., Flick M.J., Kombrinck K.W., et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105 1 (2005) 178-185
32. Im J.H., Fu W., Wang H., Bhatia S.K., Hammer D.A., Kowalska M.A., et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64 23 (2004) 8613-8619
33. Kirszberg C., Rumjanek V.M., and Monteiro R.Q. Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. Thromb Res 115 1-2 (2005) 123-129